Skip to main content
ADMA
NASDAQ Life Sciences

FDA Expands ASCENIV™ Label to Include Pediatric Patients Two Years and Older

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.63
Mkt Cap
$2.444B
52W Low
$7.21
52W High
$24.19
52W Position info
47% above low
Off High info
56% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ADMA sits 47% above its 52-week low of $7.21.

Summary

ADMA Biologics announced that the FDA has approved the expansion of the label for its product, ASCENIV™, to include pediatric immune compromised patients two years of age and older. This approval significantly broadens the addressable market for ASCENIV™, which was previously indicated only for patients aged 12 years and older. This regulatory milestone is a substantial positive catalyst, as it allows ADMA to target a new, younger patient demographic, potentially driving increased sales and market penetration for a key product. Traders will be watching for future sales data and management's updated revenue projections related to this expanded indication.

At the time of this announcement, ADMA was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.21 to $24.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ADMA - Latest Insights

ADMA
Nov 04, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.00
Real-time Price: $13.65 info
Change: -$0.350 (-2%) info
Market Cap: $3.035B info
ADMA
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.14
Real-time Price: $13.65 info
Change: +$2.51 (+23%) info
Market Cap: $3.035B info
ADMA
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.98
Real-time Price: $13.65 info
Change: +$3.67 (+37%) info
Market Cap: $3.035B info
ADMA
Aug 05, 2026, 5:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.11
Real-time Price: $13.65 info
Change: +$4.54 (+50%) info
Market Cap: $3.035B info
ADMA
Jul 16, 2026, 10:09 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $8.88
Real-time Price: $13.65 info
Change: +$4.77 (+54%) info
Market Cap: $3.035B info